Company Filing History:
Years Active: 2003-2014
Title: Chris Saris: Innovator in Antibody Research
Introduction
Chris Saris is a notable inventor based in Newbury Park, CA (US). He has made significant contributions to the field of antibody research, holding a total of 3 patents. His work focuses on innovative methods that have the potential to impact medical treatments and diagnostics.
Latest Patents
One of his latest patents is titled "Methods of using antibodies to block human thymic stromal lymphopoietin (TSLP) receptor activity." This invention provides Thymic Stromal Lymphopoietin Receptor (TSLPR) polypeptides and nucleic acid molecules encoding the same. The invention also includes selective binding agents, vectors, host cells, and methods for producing TSLPR polypeptides. Furthermore, it offers pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TSLPR polypeptides. Another significant patent is "Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family." This patent discloses novel TNF receptor polypeptides, along with polynucleotides encoding the polypeptides and their uses.
Career Highlights
Chris Saris is currently associated with Amgen Inc., a leading biotechnology company known for its innovative approaches to healthcare. His work at Amgen has allowed him to further his research and contribute to advancements in the field.
Collaborations
One of his notable coworkers is Ming-Shi Chang, with whom he has collaborated on various projects related to his research.
Conclusion
Chris Saris is a prominent inventor whose work in antibody research has led to significant advancements in medical science. His patents reflect his commitment to innovation and the potential to improve healthcare outcomes.